深圳麦科田生物医疗技术股份有限公司（麦科田，股票代码：02041）于2026年10月6日披露截至2026年9月30日的股份变动月报。报告显示，公司注册股本合计为538,626,686股，共包含479,221,686股H股及59,405,000股未上市境内股份，与上月末保持一致。
报告期内，各类股份均无新增发行、购回、注销及库存股份变动，已发行股份总数维持在538,626,686股。公司披露已于2024年12月16日通过并采纳首次公开发售前购股权计划，合计授出23,872,500份购股权，本月内无行使、授予或失效的情况。
公司确认，其已遵守香港联交所《上市规则》及其他适用的法律法规，本月股本整体保持稳定。以上公告由公司联席公司秘书颜仁仲签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.